Zymeworks (NASDAQ:ZYME) Releases Quarterly Earnings Results, Misses Estimates By $0.49 EPS

Zymeworks (NASDAQ:ZYME) posted its quarterly earnings results on Thursday. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.49), FiscalAI reports. Zymeworks had a negative return on equity of 26.00% and a negative net margin of 76.56%.The business had revenue of $2.41 million for the quarter, compared to analyst estimates of $24.38 million. During the same quarter in the previous year, the firm posted ($0.30) earnings per share. The business’s revenue was down 91.1% compared to the same quarter last year.

Here are the key takeaways from Zymeworks’ conference call:

• Zanidatamab regulatory catalysts: U.S. PDUFA is set for August 25, 2026 for first‑line HER2+ GEA and an sBLA was completed in China, creating near‑term commercialization visibility and expected partner milestone payments (approximately $250M U.S., $50M China).
• Pan‑RAS ADC platform progress: AACR disclosed three new pan‑RAS ADC candidates with a proprietary payload showing tumor‑selective accumulation, durable pathway inhibition, and encouraging non‑human primate tolerability, supporting further development across RAS‑driven cancers.
• ZW191 clinical signal: Phase I data showed strong activity in heavily pretreated ovarian (ORR 56% overall; 61% at 6.4–9.6 mg/kg) and endometrial cancer (ORR 40% overall; 57% at 6.4–9.6 mg/kg) with manageable cytopenias/GI events and ongoing dose optimization.
• Financial results show volatility: revenue fell to $2.4M (Q1 2026) from $27.1M a year earlier and net loss widened to $44.2M, driven by the absence of non‑recurring 2025 milestones and declines in development support.
• Balance sheet and capital deployment: Cash and marketable securities were $403.8M at March 31, 2026, ~$95.8M of a $125M buyback executed (≈3.93M shares), and management expects runway beyond 2028 assuming anticipated milestone payments (~$440M), supporting buybacks, partnerships, or M&A optionality.

Zymeworks Stock Performance

Shares of NASDAQ ZYME traded down $1.01 during midday trading on Thursday, reaching $26.60. 707,366 shares of the stock were exchanged, compared to its average volume of 534,479. The stock has a market capitalization of $1.96 billion, a P/E ratio of -24.63 and a beta of 1.20. The company has a 50 day simple moving average of $25.62 and a 200 day simple moving average of $24.06. Zymeworks has a twelve month low of $10.86 and a twelve month high of $29.75.

Institutional Investors Weigh In On Zymeworks

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. raised its position in Zymeworks by 1.6% in the fourth quarter. Russell Investments Group Ltd. now owns 58,350 shares of the company’s stock valued at $1,536,000 after purchasing an additional 902 shares during the period. Campbell & CO Investment Adviser LLC grew its holdings in shares of Zymeworks by 3.4% during the 4th quarter. Campbell & CO Investment Adviser LLC now owns 33,588 shares of the company’s stock worth $884,000 after purchasing an additional 1,095 shares during the period. Swiss National Bank increased its position in shares of Zymeworks by 1.5% during the 4th quarter. Swiss National Bank now owns 74,200 shares of the company’s stock worth $1,954,000 after purchasing an additional 1,100 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Zymeworks by 29.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock valued at $62,000 after buying an additional 1,131 shares during the period. Finally, O Shaughnessy Asset Management LLC lifted its position in Zymeworks by 3.1% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 43,052 shares of the company’s stock valued at $1,134,000 after buying an additional 1,284 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ZYME shares. Stifel Nicolaus boosted their target price on Zymeworks from $40.00 to $47.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a report on Monday, April 20th. Truist Financial upgraded Zymeworks to a “strong-buy” rating in a research report on Monday, April 27th. Leerink Partners upped their target price on Zymeworks from $52.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday, March 3rd. Finally, HC Wainwright raised their target price on Zymeworks from $32.00 to $46.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Zymeworks currently has an average rating of “Moderate Buy” and a consensus price target of $37.89.

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.